Vicarious Surgical（RBOT）株式概要バイカリアス・サージカル社は、米国でシングルポート手術用ロボットを開発・販売している。 詳細RBOT ファンダメンタル分析スノーフレーク・スコア評価1/6将来の成長0/6過去の実績0/6財務の健全性3/6配当金0/6リスク分析過去5年間で収益は年間22.9%減少しました。 収益が 100 万ドル未満 ( $0 )キャッシュランウェイが1年未満である US市場と比較して、過去 3 か月間の株価の変動が非常に大きい+3 さらなるリスクすべてのリスクチェックを見るRBOT Community Fair Values Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.Analyst Price TargetsAN95.4% undervaluedAnalystConsensusTarget•3mo agoLong-Term Robotic Surgery Adoption And Design Freeze Milestones Will Support A Bullish Thesis2402Top Analyst NarrativesVicarious SurgicalANAnalystConsensusTargetBased on Analyst Price TargetsLong-Term Robotic Surgery Adoption And Design Freeze Milestones Will Support A Bullish ThesisCatalysts About Vicarious Surgical Vicarious Surgical is developing a robotic surgical system designed for minimally invasive procedures. What are the underlying business or industry changes driving this perspective?View narrativeUS$5FV95.4% 割安 内在価値ディスカウントSet Fair ValueView24users have viewed this narrative0users have liked this narrative0users have commented on this narrative2users have followed this narrative4 months ago author updated this narrativeView all narrativesVicarious Surgical Inc. 競合他社Escalon MedicalSymbol: OTCPK:ESMCMarket cap: US$1.3mCatheter PrecisionSymbol: NYSEAM:VTAKMarket cap: US$2.3mINVO FertilitySymbol: NasdaqCM:IVFMarket cap: US$2.7mSonendoSymbol: OTCPK:SONXMarket cap: US$2.9m価格と性能株価の高値、安値、推移の概要Vicarious Surgical過去の株価現在の株価US$0.2352週高値US$13.7552週安値US$0.17ベータ1.771ヶ月の変化-76.84%3ヶ月変化-76.04%1年変化-97.12%3年間の変化-99.61%5年間の変化-99.90%IPOからの変化-99.90%最新ニュースお知らせ • May 15Vicarious Surgical Inc Demonstrates Sustained System Performance And Complex Hernia Procedure Workflows In Pre-Clinical SettingVicarious Surgical Inc. announced the successful completion of a full-day synthetic abdominal model lab demonstrating sustained system performance and continued procedural workflow progression for the Vicarious Surgical System. During the lab, the Vicarious Surgical System operated fully draped for multiple hours while the CMO, an experienced abdominal surgeon, performed back-to-back IPOM+ and robotic transabdominal preperitoneal (rTAPP) ventral hernia repair workflows. The lab was conducted using the Company’s integrated instrument suite, including needle drivers, graspers, monopolar scissors and electrosurgical energy. The lab represents an important progression beyond the Company’s previously announced integrated benchtop testing milestone by extending validation of the Vicarious Surgical System into sustained procedural workflows under clinically relevant operating conditions. The testing demonstrated continued progress in runtime stability, visualization, instrument control and workflow execution as the Company advances toward design freeze and future cadaveric and in-vivo studies. The Company intends to continue expanding procedural workflow testing and system validation activities as it advances development of the Vicarious Surgical System for ventral hernia repair and other abdominal procedures.お知らせ • Apr 01Vicarious Surgical Inc. Completes Integrated Benchtop Testing of Full Surgical Instrument Suite for Ventral Hernia RepairVicarious Surgical Inc. announced the successful completion of initial integrated benchtop testing for its full suite of surgical instruments, required for its anticipated first clinical indication of ventral hernia repair, marking an important step toward design validation, clinical readiness, and the Company’s targeted design freeze milestone. This milestone represents the first system-level performance evaluation of the Company's three core instruments: needle drivers, fenestrated graspers, and monopolar scissors, each of which is designed for use with the Vicarious Surgical System. The successful testing of all three instruments in a unified evaluation serves as a critical step in systematically de-risking the Company's path toward first-in-human use. Notably, the monopolar scissors, which previously demonstrated successful electrical performance in a December porcine lab study, exhibited strong motion and mechanical cutting capabilities following the Company's standard automated calibration and bring-up process. Importantly, instrument and camera sensors remained stable, with no degradation in video or motion quality in the presence of monopolar electrosurgical energy, confirming robust system performance under clinically relevant operating conditions. The successful completion of this benchtop testing positions the Company to advance to the next phase of preclinical validation, including planned cadaveric and porcine studies, as it continues to prepare for first clinical use of the Vicarious Surgical System and execute against a defined series of development milestones leading to design freeze.お知らせ • Mar 07+ 9 more updatesVicarious Surgical Inc.(OTCPK:RBOT) dropped from Russell Microcap Value IndexVicarious Surgical Inc.(OTCPK:RBOT) dropped from Russell Microcap Value Index新しいナラティブ • Mar 06Long-Term Robotic Surgery Adoption And Design Freeze Milestones Will Support A Bullish ThesisCatalysts About Vicarious Surgical Vicarious Surgical is developing a robotic surgical system designed for minimally invasive procedures. What are the underlying business or industry changes driving this perspective?お知らせ • Mar 05Vicarious Surgical Inc. Receives Delisting Notice From NYSEOn March 3, 2026, the New York Stock Exchange (the NYSE) notified Vicarious Surgical Inc. (the Company) that the NYSE had determined to (A) immediately suspend trading in the Company's common stock, par value $0.0001 per share (the Common Stock), due to a determination that the Company had fallen below the NYSE's continued listing standard requiring listed companies to maintain an average global market capitalization over a consecutive 30 trading day period of at least $15,000,000 pursuant to Section 802.01B of the NYSE Listed Company Manual, and (B) commence proceedings to delist the Common Stock. The NYSE has stated that it will apply to the Securities and Exchange Commission to delist the Common Stock by filing a Form 25 upon completion of all applicable procedures, including any appeal by the Company of the NYSE's delisting determination, which appeal must be made within ten business days from receipt of the determination. The Company is currently evaluating whether to appeal the delisting determination. The Company has received approval of its application to have the Common Stock quoted on the OTCID market tier (OTCID) operated by the OTC Markets Group Inc. (OTC Markets). The Company expects that the Common Stock will commence quotation on the OTCID at the open of business on March 4, 2026 under the current trading symbol of RBOT. The OTCID is a significantly more limited market than the NYSE, and quotation on any OTC market will result in a less liquid market for existing and potential holders of the Common Stock to trade the Common Stock and could further depress the trading price of the Common Stock. The Company can provide no assurance that the Common Stock will continue to trade on this market, whether broker-dealers will provide and continue to provide public quotes of the Common Stock on this market, or whether the trading volume of the Common Stock will be sufficient to provide for an efficient trading market. The suspension and/or delisting of the Company's common stock from the NYSE could negatively impact the Company by (i) reducing the liquidity and market price of the Common Stock; (ii) reducing the number of investors willing to hold or acquire the Common Stock, which could negatively impact the Company's ability to raise equity financing; (iii) impacting the Company's ability to use a registration statement to offer and sell freely tradable securities, thereby preventing the Company from accessing the public capital markets; and (iv) impairing the Company's ability to provide equity incentives to its employees.New Risk • Feb 21New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$51m net loss in 2 years). Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (US$13.1m market cap).最新情報をもっと見るRecent updatesお知らせ • May 15Vicarious Surgical Inc Demonstrates Sustained System Performance And Complex Hernia Procedure Workflows In Pre-Clinical SettingVicarious Surgical Inc. announced the successful completion of a full-day synthetic abdominal model lab demonstrating sustained system performance and continued procedural workflow progression for the Vicarious Surgical System. During the lab, the Vicarious Surgical System operated fully draped for multiple hours while the CMO, an experienced abdominal surgeon, performed back-to-back IPOM+ and robotic transabdominal preperitoneal (rTAPP) ventral hernia repair workflows. The lab was conducted using the Company’s integrated instrument suite, including needle drivers, graspers, monopolar scissors and electrosurgical energy. The lab represents an important progression beyond the Company’s previously announced integrated benchtop testing milestone by extending validation of the Vicarious Surgical System into sustained procedural workflows under clinically relevant operating conditions. The testing demonstrated continued progress in runtime stability, visualization, instrument control and workflow execution as the Company advances toward design freeze and future cadaveric and in-vivo studies. The Company intends to continue expanding procedural workflow testing and system validation activities as it advances development of the Vicarious Surgical System for ventral hernia repair and other abdominal procedures.お知らせ • Apr 01Vicarious Surgical Inc. Completes Integrated Benchtop Testing of Full Surgical Instrument Suite for Ventral Hernia RepairVicarious Surgical Inc. announced the successful completion of initial integrated benchtop testing for its full suite of surgical instruments, required for its anticipated first clinical indication of ventral hernia repair, marking an important step toward design validation, clinical readiness, and the Company’s targeted design freeze milestone. This milestone represents the first system-level performance evaluation of the Company's three core instruments: needle drivers, fenestrated graspers, and monopolar scissors, each of which is designed for use with the Vicarious Surgical System. The successful testing of all three instruments in a unified evaluation serves as a critical step in systematically de-risking the Company's path toward first-in-human use. Notably, the monopolar scissors, which previously demonstrated successful electrical performance in a December porcine lab study, exhibited strong motion and mechanical cutting capabilities following the Company's standard automated calibration and bring-up process. Importantly, instrument and camera sensors remained stable, with no degradation in video or motion quality in the presence of monopolar electrosurgical energy, confirming robust system performance under clinically relevant operating conditions. The successful completion of this benchtop testing positions the Company to advance to the next phase of preclinical validation, including planned cadaveric and porcine studies, as it continues to prepare for first clinical use of the Vicarious Surgical System and execute against a defined series of development milestones leading to design freeze.お知らせ • Mar 07+ 9 more updatesVicarious Surgical Inc.(OTCPK:RBOT) dropped from Russell Microcap Value IndexVicarious Surgical Inc.(OTCPK:RBOT) dropped from Russell Microcap Value Index新しいナラティブ • Mar 06Long-Term Robotic Surgery Adoption And Design Freeze Milestones Will Support A Bullish ThesisCatalysts About Vicarious Surgical Vicarious Surgical is developing a robotic surgical system designed for minimally invasive procedures. What are the underlying business or industry changes driving this perspective?お知らせ • Mar 05Vicarious Surgical Inc. Receives Delisting Notice From NYSEOn March 3, 2026, the New York Stock Exchange (the NYSE) notified Vicarious Surgical Inc. (the Company) that the NYSE had determined to (A) immediately suspend trading in the Company's common stock, par value $0.0001 per share (the Common Stock), due to a determination that the Company had fallen below the NYSE's continued listing standard requiring listed companies to maintain an average global market capitalization over a consecutive 30 trading day period of at least $15,000,000 pursuant to Section 802.01B of the NYSE Listed Company Manual, and (B) commence proceedings to delist the Common Stock. The NYSE has stated that it will apply to the Securities and Exchange Commission to delist the Common Stock by filing a Form 25 upon completion of all applicable procedures, including any appeal by the Company of the NYSE's delisting determination, which appeal must be made within ten business days from receipt of the determination. The Company is currently evaluating whether to appeal the delisting determination. The Company has received approval of its application to have the Common Stock quoted on the OTCID market tier (OTCID) operated by the OTC Markets Group Inc. (OTC Markets). The Company expects that the Common Stock will commence quotation on the OTCID at the open of business on March 4, 2026 under the current trading symbol of RBOT. The OTCID is a significantly more limited market than the NYSE, and quotation on any OTC market will result in a less liquid market for existing and potential holders of the Common Stock to trade the Common Stock and could further depress the trading price of the Common Stock. The Company can provide no assurance that the Common Stock will continue to trade on this market, whether broker-dealers will provide and continue to provide public quotes of the Common Stock on this market, or whether the trading volume of the Common Stock will be sufficient to provide for an efficient trading market. The suspension and/or delisting of the Company's common stock from the NYSE could negatively impact the Company by (i) reducing the liquidity and market price of the Common Stock; (ii) reducing the number of investors willing to hold or acquire the Common Stock, which could negatively impact the Company's ability to raise equity financing; (iii) impacting the Company's ability to use a registration statement to offer and sell freely tradable securities, thereby preventing the Company from accessing the public capital markets; and (iv) impairing the Company's ability to provide equity incentives to its employees.New Risk • Feb 21New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$51m net loss in 2 years). Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (US$13.1m market cap).お知らせ • Jan 13Vicarious Surgical Advances Toward Design Freeze with Successful In-Vivo Porcine LabVicarious Surgical announced the successful completion of an in-vivo porcine lab conducted in December 2025, marking a meaningful step forward in the development of the company's robotic system and reinforcing progress toward system design freeze targeted for the end of 2026. During the lab, surgeons independently completed key elements of a ventral hernia repair using Vicarious Surgical's pre-DV system as part of a limited-scope feasibility assessment. In parallel, the company executed a series of targeted technical evaluations designed to assess system performance against key engineering and functional specifications. Data generated during the lab, along with structured surgeon feedback, are being incorporated into ongoing design refinement, verification planning, and system optimization efforts. The December in-vivo lab builds on Vicarious Surgical's disciplined, specification-driven development approach and reflects the company's focus on minimizing technical risk through iterative testing, surgeon engagement, and data-driven execution at this stage of system integration. This marks the Company's first in-vivo animal lab conducted in several years, and the first performed with an integrated system architecture rather than early-stage prototypes, providing critical insight into system behavior under realistic surgical conditions. The lab was conducted for research and development purposes only and was not designed to support regulatory submissions or clinical claims.New Risk • Dec 26New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$51m net loss in 2 years). Market cap is less than US$100m (US$13.3m market cap).お知らせ • Dec 13Vicarious Surgical Inc. has filed a Follow-on Equity Offering in the amount of $3 million.Vicarious Surgical Inc. has filed a Follow-on Equity Offering in the amount of $3 million. Security Name: Class A Common Stock Security Type: Common Stock Transaction Features: At the Market Offeringお知らせ • Dec 03Vicarious Surgical Inc. Announces Board and Committee ChangesOn December 1, 2025, Beverly Huss and Randy Clark each resigned as a member of the Board of Directors of Vicarious Surgical Inc., effective as of the Effective Date. Ms. Huss's and Mr. Clark's resignations were tendered in connection with a decision by the Board to reduce its size, and did not result from any disagreement regarding the Company's operations, policies or practices. In connection with Ms. Huss's and Mr. Clark's resignations, the Board reduced its size from nine members to seven as of the Effective Date. To address the resulting committee vacancies, Joseph Doherty was appointed as a member of the Audit Committee of the Board, Fuad Ahmad was appointed as a member of the Compensation Committee of the Board (the Compensation Committee"), and Victoria Carr-Brendel was appointed as Chair of the Compensation Committee, in each case effective as of the Effective Date.New Risk • Nov 20New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 0.9% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 0.9% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$53m net loss in 2 years). Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (US$19.4m market cap).Price Target Changed • Nov 13Price target decreased by 16% to US$9.00Down from US$10.75, the current price target is an average from 2 analysts. New target price is 159% above last closing price of US$3.48. Stock is down 67% over the past year. The company is forecast to post a net loss per share of US$7.99 next year compared to a net loss per share of US$10.74 last year.お知らせ • Oct 31Vicarious Surgical Inc. to Report Q3, 2025 Results on Nov 13, 2025Vicarious Surgical Inc. announced that they will report Q3, 2025 results After-Market on Nov 13, 2025New Risk • Oct 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings are forecast to decline by an average of 4.1% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$65m net loss in 2 years). Market cap is less than US$100m (US$39.2m market cap).お知らせ • Oct 08Vicarious Surgical Inc. has filed a Follow-on Equity Offering in the amount of $5.864944 million.Vicarious Surgical Inc. has filed a Follow-on Equity Offering in the amount of $5.864944 million. Security Name: Class A Common stock Security Type: Common Stock Securities Offered: 588,300 Price\Range: $5.1 Discount Per Security: $0.306 Security Name: Pre-funded warrants Security Type: Equity Warrant Securities Offered: 561,700 Price\Range: $5.0999 Discount Per Security: $0.306 Transaction Features: Registered Direct Offeringお知らせ • Sep 26Vicarious Surgical Inc. Announces Appointment of Joseph Doherty as Chairman of the BoardVicarious Surgical Inc. announced the appointment of Joseph Doherty as Chairman of the Company’s Board of Directors . Mr. Doherty has served as a member of the Board since June 2025. Since January 2025, Mr. Doherty has served as CEO of the Worcester City Campus Corporation, a not-for-profit corporation whose base corporate purpose is to foster, promote and support the University of Massachusetts. Mr. Doherty has held a range of senior leadership positions across the healthcare and medical device industries. He served as President of Scapa Healthcare and sat on the Board of Directors of Scapa Group, a publicly traded company on the AIM Stock Exchange. He was also President of Olympus Surgical Technologies America, a subsidiary of Olympus Corporation of the Americas. Earlier in his career, he spent 24 years at Johnson & Johnson in roles of increasing responsibility, ultimately serving as Vice President of Integration and Transformation. In addition to his executive experience, Mr. Doherty has served on the boards of the Massachusetts Biomedical Initiative, Immertec, and ZATA Pharmaceuticals, and as an advisor to AccuTec and Boardwalk Robotics. He earned a Bachelor of Science in Engineering from the United States Military Academy at West Point and a Master of Business Administration from Nichols College.お知らせ • Sep 17Vicarious Surgical Inc. Announces Board ChangesOn September 12, 2025, Donald Tang resigned as a member of the Board of Directors of Vicarious Surgical Inc. effective as of September 12, 2025. Mr. Tang’s resignation did not result from any disagreement regarding the Company’s operations, policies or practices. In connection with Mr. Tang’s resignation, the Board appointed Victoria Carr-Brendel as a member of the Audit Committee of the Board.New Risk • Aug 28New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: US$49k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$50m free cash flow). Earnings are forecast to decline by an average of 4.1% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$65m net loss in 2 years). Share price has been volatile over the past 3 months (16% average weekly change). Significant insider selling over the past 3 months (US$49k sold). Market cap is less than US$100m (US$39.1m market cap).New Risk • Aug 13New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 2.7% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$47m free cash flow). Earnings are forecast to decline by an average of 2.7% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$65m net loss in 2 years). Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (US$61.4m market cap).お知らせ • Aug 01+ 1 more updateVicarious Surgical Inc. Announces Chief Executive Officer ChangesVicarious Surgical Inc. announced the appointment of Stephen From as Chief Executive Officer, effective August 7, 2025. Adam Sachs, current Chief Executive Officer, Co-Founder, and a member of the Board, will remain with the Company as President, Co-Founder, and a member of the Board in an operational capacity as a member of the Company’s leadership team. Mr. From brings over 20 years of leadership in the healthcare and financial industry. He most recently served as CEO of Aruna Bio, guiding the company’s strategic direction and clinical advancement of its proprietary neural exosome platform. From October 2005 through February 2021, Mr. From served as President and CEO, and from February 2021 through January 2022 served as Executive Chairman of Kiora Pharmaceuticals Inc., formerly known as EyeGate Pharmaceuticals Inc. Before EyeGate, Mr. From was CFO of Centelion SAS, then a biotech subsidiary of Sanofi-Aventis, and spent several years in investment banking, focusing on the life sciences sector at Bank of America Securities and Robertson Stephens. Mr. From holds a Bachelor of Science from the University of Western Ontario and earned his accounting designation from Wilfrid Laurier University.お知らせ • Jul 30Vicarious Surgical Inc. to Report Q2, 2025 Results on Aug 12, 2025Vicarious Surgical Inc. announced that they will report Q2, 2025 results After-Market on Aug 12, 2025分析記事 • Jul 15Here's Why We're A Bit Worried About Vicarious Surgical's (NYSE:RBOT) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...お知らせ • Jul 13The New York Stock Exchange Accepts Compliance Plan from Vicarious Surgical and to Quarterly Review to Confirm ComplianceAs previously reported, on April 10, 2025, Vicarious Surgical Inc. (the ‘Company’) received a written notice (the ‘Notice’) from the New York Stock Exchange (the ‘NYSE’) indicating the Company was no longer in compliance with the NYSE’s continued listing standards set forth in Section 802.01B of the NYSE’s Listed Company Manual (the ‘Minimum Market Capitalization Standard’) due to the fact that the Company’s average global market capitalization over a consecutive 30 trading-day period was less than $50 million and, at the same time, its stockholders’ equity was less than $50 million. In accordance with applicable NYSE procedures, the Company timely submitted a plan (the ‘Compliance Plan’) to the NYSE advising it of the definitive actions the Company has taken, is taking, and plans to take that would bring it into conformity with the Minimum Market Capitalization Standard within 18 months of receipt of the Notice (the ‘Cure Period’). On July 8, 2025, the NYSE notified the Company that it had accepted the Compliance Plan (the ‘Acceptance Letter’). The NYSE will review the Company on a quarterly basis to confirm compliance with the Compliance Plan. If the Company fails to comply with the Compliance Plan or does not meet the Minimum Market Capitalization Standard at the end of the Cure Period, it will be subject to NYSE’s prompt initiation of suspension and delisting procedures. The Acceptance Letter has no immediate impact on the listing of the Company’s Class A common stock, which will continue to be listed and traded on the NYSE during the Cure Period, subject to the Company’s continued compliance with the Compliance Plan and NYSE’s other continued listing standards. However, the Class A common stock trading symbol will have an added designation of ‘.BC’ to indicate that the status of the Class A common stock is below criteria with the NYSE continued listing standards. The ‘.BC’ indicator will be removed at such time as the Company regains compliance. The current noncompliance with the NYSE listing standards does not affect the Company’s ongoing business operations or its U.S. Securities and Exchange Commission (the ‘Commission’) reporting requirements. The Company is considering all available options to regain compliance with NYSE’s continued listing standards.Board Change • Jul 02High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Fuad Ahmad was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.お知らせ • Jun 30Vicarious Surgical Inc. Announces Changes to Its BoardVicarious Surgical Inc. announced the election of Fuad Ahmad and Joseph Doherty to the Board of Directors at the Company’s 2025 Annual Meeting of Stockholders held on June 27, 2025. The Company also announced the departure of Ric Fulop from the Board of Directors effective as of the Annual Meeting. Mr. Ahmad has been a partner at FLG Partners, a CEO and CFO consulting practice and board advisory services firm, since 2013. From November 2020 to March 2025, he served as CFO of Iridex Corporation, a medical device company. Prior to that, Mr. Ahmad served as CFO at each of Mitek Systems, Vaxart Inc., Cutera Inc., and Telenav Inc. Prior to joining FLG Partners, he served as CFO of Sezmi Corporation, a Morgenthaler Ventures-backed cloud-based software platform. Prior to his service with Sezmi Corporation, Mr. Ahmad served as Senior Vice President and CFO of Globalstar Inc., a public company that builds and operates low-earth orbit satellite-based digital telecommunications systems. Mr. Ahmad graduated from Brigham Young University with a Bachelor of Science in Finance. Mr. Doherty has served as CEO of the Worcester City Campus Corporation since January 2025. Since 2020, Mr. Doherty has served as a teacher at Saint John’s High School, and since March 2022, he has also served as a member of the board of directors of Immertec. From 2021 to 2025, he served as the Director for the BOLT initiative at the Massachusetts Biomedical Initiative. From January 2019 to August 2020, he served as the President of Scapa Healthcare, and from January 2019 to May 2020, he was a member of the board of directors of Scapa Group. From 2015 to 2019, Mr. Doherty served in roles of increasing responsibility, including as President of Olympus Surgical Technologies America. He also spent over 24 years with Johnson & Johnson and held various roles with increasing responsibilities, ultimately serving as the Vice President of Integration and Transformation. Mr. Doherty received a Bachelor of Science in Engineering from the United States Military Academy at West Point and a Master of Business Administration from Nichols College.お知らせ • Apr 30Vicarious Surgical Inc., Annual General Meeting, Jun 27, 2025Vicarious Surgical Inc., Annual General Meeting, Jun 27, 2025.New Risk • Apr 29New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 21% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$50m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$56m net loss in 3 years). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (US$50.2m market cap).お知らせ • Apr 29Vicarious Surgical Inc. to Report Q1, 2025 Results on May 12, 2025Vicarious Surgical Inc. announced that they will report Q1, 2025 results After-Market on May 12, 2025New Risk • Apr 26New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$50m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$56m net loss in 3 years). Market cap is less than US$100m (US$39.4m market cap).お知らせ • Apr 12Vicarious Surgical Receives Continued Listing Standard Notice from the NYSEVicarious Surgical Inc. ("Vicarious Surgical" or the "Company") announced that on April 10, 2025, the Company received written notice (the "Notice") from the New York Stock Exchange (the "NYSE") indicating that the Company is no longer in compliance with the continued listing standards set under Section 802.01B of the NYSE's Listed Company Manual due to the fact that the Company's average market capitalization over a consecutive 30 trading-day period was less than $50 million and, at the same time, the Company's last reported stockholders' equity was less than $50 million. As set in the Notice, as of April 9, 2025, the 30 trading-day average market capitalization was approximately $47.4 million, and the Company's last reported stockholders' equity as of December 31, 2024 was less than $50 million. This notice does not impact the Company's business operations. In accordance with applicable NYSE procedures, the Company has 45 days from the date the Notice was received to submit a plan advising the NYSE of the definitive action(s) the Company has taken, is taking, or plans to take to bring it into compliance with Section 802.01B within 18 months of receipt of the Notice. If the Company's plan is not submitted on a timely basis or is not accepted, the NYSE will initiate delisting proceedings. Pending NYSE acceptance of the plan, the Company's Class A common stock will continue to be listed and traded on the NYSE during the 18-month cure period. Continued listing is also subject to the Company's compliance with other applicable NYSE requirements and to quarterly NYSE review of the Company's progress toward achieving compliance with the plan. In the interim, the Company's Class A common stock will continue to trade on the NYSE under the symbol "RBOT" with the designation of ".BC" to indicate the status of the shares as "below criteria," but is otherwise not immediately impacted by the Notice. The ".BC" indicator will be removed at such time as the Company regains compliance. The Notice also does not affect Securities and Exchange Commission reporting obligations by the Company. The Company is considering all available options to regain compliance with the NYSE's continued listing standards.お知らせ • Mar 25Vicarious Surgical Inc. Announces Transition of Company President, Randy Clark to Board Member, Effective April 25, 2025Vicarious Surgical Inc. announced that Company President, Randy Clark, will transition to Board Member, effective April 25, 2025, pending customary conflict checks. As President, Mr. Clark directed critical business functions, including product development, operations, clinical regulatory, quality affairs, and human resources. He spearheaded the strategic development of Vicarious Surgical’s manufacturing capabilities, establishing key partnerships and strengthening the supply chain. Notably, he implemented key personnel realignment, streamlined business processes, and formalized workflows and standardized procedures in order to position the Company for its next phase of growth.New Risk • Mar 18New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$51m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$51m free cash flow). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$56m net loss in 3 years). Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (US$56.9m market cap).分析記事 • Mar 18Is Vicarious Surgical (NYSE:RBOT) In A Good Position To Deliver On Growth Plans?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...お知らせ • Mar 13Vicarious Surgical Appoints Sarah Romano as Chief Financial Officer, Effective from April 1, 2025Vicarious Surgical announced the appointment of Sarah Romano as Chief Financial Officer, Effective date is April 1, 2025. Ms. Romano will oversee Vicarious Surgical’s financial strategy, leveraging decades of financial leadership experience in capital markets. With exceptional strategic acumen, Ms. Romano has a proven record of driving growth and value creation in public companies, particularly in the healthcare sector, through successful fundraising and M&A initiatives. Most recently, Ms. Romano served as Chief Financial Officer of Entero Therapeutics, where she oversaw financial strategy, operations, and compliance, raising significant funding and successfully executing product in-licensing partnerships. Previously, as Chief Financial Officer of Kiora Pharmaceuticals, Ms. Romano secured over $50 million in funding and spearheaded M&A activities, overseeing due diligence and integration. Earlier in her career, Ms. Romano progressed through roles of increasing responsibility, including corporate controller, with responsibilities encompassing budget reviews, financial forecasting and analysis, internal controls oversight, and SEC reporting. Ms. Romano holds a Master of Accountancy from Boston College and a B.A. in Accounting from the College of the Holy Cross.お知らせ • Mar 04Vicarious Surgical Inc. to Report Q4, 2024 Results on Mar 17, 2025Vicarious Surgical Inc. announced that they will report Q4, 2024 results at 4:00 PM, US Eastern Standard Time on Mar 17, 2025お知らせ • Feb 19Vicarious Surgical Inc. Announces Chief Operating Officer Changes, Effective April 1, 2025Vicarious Surgical Inc. announced Chief Operating Officer (COO) John Mazzola will retire, effective April 1, 2025, after nearly 40 years in healthcare manufacturing, supply chain and quality control. Mr. Mazzola will continue to serve as COO until the effective date, at which time his responsibilities will transition to Randy Clark, Company President.お知らせ • Dec 08Vicarious Surgical Inc. Announces Departure of William Kelly as Chief Financial Officer, Effective January 2, 2025Vicarious Surgical Inc. announced the pending departure of William Kelly, its Chief Financial Officer (CFO), to pursue other career opportunities, after nearly four years of dedicated service with the Company. Mr. Kelly has served as Vicarious Surgical’s CFO since January 2021. He will assist the Company to ensure minimal disruption and a successful transition of responsibilities prior to his departure, which is slated for January 2, 2025. The Company has initiated a CFO succession process and will provide updates as appropriate.分析記事 • Nov 30We're Keeping An Eye On Vicarious Surgical's (NYSE:RBOT) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Price Target Changed • Nov 15Price target increased by 18% to US$11.17Up from US$9.50, the current price target is an average from 3 analysts. New target price is 19% above last closing price of US$9.36. Stock is up 0.6% over the past year. The company is forecast to post a net loss per share of US$11.04 next year compared to a net loss per share of US$14.60 last year.New Risk • Nov 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings are forecast to decline by an average of 3.8% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$70m net loss in 3 years). Shareholders have been diluted in the past year (2.7% increase in shares outstanding). Market cap is less than US$100m (US$49.5m market cap).お知らせ • Oct 29Vicarious Surgical Inc. to Report Q3, 2024 Results on Nov 12, 2024Vicarious Surgical Inc. announced that they will report Q3, 2024 results After-Market on Nov 12, 2024分析記事 • Aug 16Here's Why Vicarious Surgical (NYSE:RBOT) Must Use Its Cash WiselyThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...お知らせ • Jul 30Vicarious Surgical Inc. to Report Q2, 2024 Results on Aug 12, 2024Vicarious Surgical Inc. announced that they will report Q2, 2024 results After-Market on Aug 12, 2024Price Target Changed • Jul 16Price target increased by 21% to US$37.50Up from US$31.00, the current price target is an average from 2 analysts. New target price is 340% above last closing price of US$8.53. Stock is down 86% over the past year. The company is forecast to post a net loss per share of US$11.28 next year compared to a net loss per share of US$14.60 last year.お知らせ • Apr 24Vicarious Surgical Inc., Annual General Meeting, Jun 10, 2024Vicarious Surgical Inc., Annual General Meeting, Jun 10, 2024, at 14:00 US Eastern Standard Time. Agenda: To elect seven directors to serve one-year terms expiring in 2025; to approve an amendment to the Vicarious Surgical Inc. 2021 Equity Incentive Plan (the Plan) to increase the number of shares of common stock authorized for issuance under the Plan by 5,000,000 shares; to approve an amendment to the Companys Certificate of Incorporation, as amended (the Certificate of Incorporation), to effect a reverse stock split.お知らせ • Apr 09Vicarious Surgical Inc. to Report Q1, 2024 Results on Apr 29, 2024Vicarious Surgical Inc. announced that they will report Q1, 2024 results After-Market on Apr 29, 2024New Risk • Mar 05New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 0.1% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (28% average weekly change). Earnings are forecast to decline by an average of 0.1% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$82m net loss in 3 years). Shareholders have been diluted in the past year (40% increase in shares outstanding). Market cap is less than US$100m (US$63.3m market cap).分析記事 • Mar 05Is Vicarious Surgical (NYSE:RBOT) In A Good Position To Invest In Growth?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...お知らせ • Feb 13Vicarious Surgical Inc. to Report Q4, 2023 Results on Mar 04, 2024Vicarious Surgical Inc. announced that they will report Q4, 2023 results After-Market on Mar 04, 2024お知らせ • Jan 30Vicarious Surgical Inc. Announces Management ChangesVicarious Surgical Inc. announced that Randy Clark has been appointed President effective, January 29, 2024. Reporting to Chief Executive Officer Adam Sachs, Mr. Clark will assume responsibility for the day-to-day oversight of many core business functions including product development, operations, commercial strategy, clinical, regulatory and quality affairs, and human resources. Mr. Clark joins as an accomplished leader with more than 20 years of medical device industry experience and has been instrumental in the development, manufacture, and commercialization of several innovative medical device solutions throughout his career. Most recently, Mr. Clark served as the Global President of the Health Solutions Business Unit at Flex Ltd., a prominent global supply chain, manufacturing, and design solutions provider. Prior to this, he spent 15 years at Olympus Corporation of the Americas, where he held various roles with increasing responsibilities, ultimately serving as President and a member of their board of directors, overseeing full P&L management for the Americas. Mr. Clark earned a Bachelor of Science in Business Administration from Drake University, a Master of Business Administration degree from Colorado State University, and completed the Advanced Management program at Harvard Business School. In connection with the appointment of Mr. Clark, Adam Sachs stepped down from his role as President. Mr. Sachs will continue to serve as the Chief Executive Officer of the Company.分析記事 • Nov 24Is Vicarious Surgical (NYSE:RBOT) In A Good Position To Invest In Growth?We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Price Target Changed • Nov 17Price target decreased by 84% to US$1.13Down from US$7.00, the current price target is an average from 3 analysts. New target price is 319% above last closing price of US$0.27. Stock is down 92% over the past year. The company is forecast to post a net loss per share of US$0.56 compared to earnings per share of US$0.042 last year.お知らせ • Oct 27Vicarious Surgical Inc. to Report Q3, 2023 Results on Nov 13, 2023Vicarious Surgical Inc. announced that they will report Q3, 2023 results After-Market on Nov 13, 2023New Risk • Oct 03New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$89.6m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$50m net loss in 3 years). Shareholders have been diluted in the past year (41% increase in shares outstanding). Significant insider selling over the past 3 months (US$99k sold). Market cap is less than US$100m (US$89.6m market cap).お知らせ • Sep 24Vicarious Surgical Receives Continued Listing Standard Notice From NYSEVicarious Surgical Inc. announced that on September 20, 2023, it received a notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that it is not in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company’s Class A common stock was less than $1.00 per share over a consecutive 30 trading-day period. The Notice does not result in the immediate delisting of the Company’s Class A common stock from the NYSE. The Company intends to respond to the NYSE within ten business days of receipt of the Notice affirming its intent to cure the stock price deficiency and to return to compliance with the NYSE continued listing standard. Pursuant to the NYSE’s rules, the Company has a six-month period following receipt of the Notice to regain compliance with the NYSE’s minimum share price requirement. The Company can regain compliance with the minimum share price requirement at any time during the cure period if, on the last trading day of any calendar month during the cure period, or on the last day of the cure period, the Company’s Class A common stock has (i) a closing share price of at least $1.00, and (ii) an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of that month or on the last day of the cure period, as applicable. The Company intends to consider available alternatives, including, but not limited to, a reverse stock split, subject to Board and stockholder approval at the Company’s next annual meeting, to regain compliance. The Company’s Class A common stock will continue to be listed and traded on the NYSE during this period, subject to its compliance with other NYSE continued listing standards. The receipt of the Notice does not affect the Company’s business, operations or reporting requirements with the Securities and Exchange Commission.Seeking Alpha • Aug 24Vicarious Surgical: Huge Potential But Low Margin Of Safety To CommercializationSummary Vicarious Surgical is a surgical robotics company developing a next-generation surgical robot with human-like dexterity. The company has a large addressable market of over 45 million abdominal procedures worth $150 billion, but its survival is uncertain due to low cash reserves and high burn. I am personally staying on the sidelines as I believe the risk / reward is better if/when RBOT reaches commercialization with a superior product than currently awaiting regulatory approval. Read the full article on Seeking AlphaNew Risk • Aug 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$50m net loss in 3 years). Share price has been volatile over the past 3 months (15% average weekly change). Shareholders have been diluted in the past year (42% increase in shares outstanding). Significant insider selling over the past 3 months (US$147k sold).分析記事 • Jul 18Here's Why We're Watching Vicarious Surgical's (NYSE:RBOT) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...お知らせ • Jul 14Vicarious Surgical Inc. to Report Q2, 2023 Results on Jul 27, 2023Vicarious Surgical Inc. announced that they will report Q2, 2023 results After-Market on Jul 27, 2023New Risk • Jun 29New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: US$147k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$62m net loss in 3 years). Shareholders have been diluted in the past year (4.7% increase in shares outstanding). Significant insider selling over the past 3 months (US$147k sold).Recent Insider Transactions • May 27Co-Founder recently sold US$54k worth of stockOn the 22nd of May, Adam Sachs sold around 24k shares on-market at roughly US$2.24 per share. This transaction amounted to 11% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Adam has been a net seller over the last 12 months, reducing personal holdings by US$325k.Seeking Alpha • May 26Vicarious Surgical: Cash Burn Adds To Downside RiskSummary RBOT is attempting to commercialize a novel robotic surgery system with virtual reality capabilities. Commercialization is only expected in 2025 pending certifications and medical device approval. The company is bleeding cash and will likely require a major capital raise in the next year. Read the full article on Seeking AlphaRecent Insider Transactions Derivative • May 26Co-Founder notifies of intention to sell stockAdam Sachs intends to sell 24k shares in the next 90 days after lodging an Intent To Sell Form on the 22nd of May. If the sale is conducted around the recent share price of US$2.07, it would amount to US$50k. For the year to December 2020, Adam's total compensation was 11% salary and 89% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since June 2022, Adam's direct individual holding has increased from 11.30m shares to 11.39m. Company insiders have collectively bought US$245k more than they sold, via options and on-market transactions, in the last 12 months.お知らせ • May 19Vicarious Surgical Inc. Announces Promotion of John Mazzola to Chief Operating OfficerVicarious Surgical Inc. announced the promotion of John Mazzola to Chief Operating Officer. John joined Vicarious Surgical in March of 2022 as SVP of Operations and has over 35 years of medical device industry experience. He has been involved with over 25 medical device product launches encompassing both Class II and Class III devices. Prior to joining the Vicarious Surgical team, he spent 13 years in senior executive roles and product development leadership positions, including serving as VP of Operations at Becton Dickinson Surgery overseeing a network of 10 manufacturing sites, a business planning and procurement organization, an advanced manufacturing engineering team, and the business’ environmental health and safety responsibilities. In the past year, John has led strategic manufacturing plans for the Vicarious Surgical robotic system, overseeing operations and quality organizations. In the newly created Chief Operating Officer role, John’s oversight expands to include the Product Development, Clinical & Regulatory Affairs, IT and People & Culture functions of the business for enhanced workflow efficiency and a continued focus on manufacturing and procurement optimization.Recent Insider Transactions • Mar 31Insider recently bought US$153k worth of stockOn the 27th of March, Philip Liang bought around 74k shares on-market at roughly US$2.07 per share. This transaction amounted to 3.6% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth US$241k. Insiders have collectively bought US$220k more in shares than they have sold in the last 12 months.Valuation Update With 7 Day Price Move • Mar 25Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to US$1.90, the stock trades at a trailing P/E ratio of 46.4x. Average forward P/E is 31x in the Medical Equipment industry in the US. Total loss to shareholders of 57% over the past year.Recent Insider Transactions • Mar 17Insider recently bought US$139k worth of stockOn the 13th of March, Philip Liang bought around 59k shares on-market at roughly US$2.36 per share. This transaction amounted to 3.1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth US$241k. Despite this recent purchase, insiders have collectively sold US$134k more in shares than they bought in the last 12 months.Recent Insider Transactions • Mar 10Insider recently bought US$78k worth of stockOn the 2nd of March, Philip Liang bought around 30k shares on-market at roughly US$2.60 per share. This transaction amounted to 1.7% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth US$241k. Despite this recent purchase, insiders have collectively sold US$366k more in shares than they bought in the last 12 months.Recent Insider Transactions • Feb 27Co-Founder recently sold US$65k worth of stockOn the 21st of February, Adam Sachs sold around 24k shares on-market at roughly US$2.78 per share. This transaction amounted to 14% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Adam has been a net seller over the last 12 months, reducing personal holdings by US$260k.Recent Insider Transactions Derivative • Feb 26Co-Founder notifies of intention to sell stockAdam Sachs intends to sell 24k shares in the next 90 days after lodging an Intent To Sell Form on the 21st of February. If the sale is conducted around the recent share price of US$3.06, it would amount to US$72k. For the year to December 2020, Adam's total compensation was 5% salary and 95% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2022, Adam's direct individual holding has increased from 11.33m shares to 11.34m. Company insiders have collectively sold US$906k more than they bought, via options and on-market transactions in the last 12 months.Valuation Update With 7 Day Price Move • Feb 22Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to US$2.75, the stock trades at a trailing P/E ratio of 67.2x. Average forward P/E is 32x in the Medical Equipment industry in the US. Total loss to shareholders of 51% over the past year.Price Target Changed • Feb 16Price target decreased by 21% to US$7.75Down from US$9.75, the current price target is an average from 4 analysts. New target price is 139% above last closing price of US$3.24. Stock is down 47% over the past year. The company is forecast to post a net loss per share of US$0.59 compared to earnings per share of US$0.042 last year.Recent Insider Transactions • Feb 14Insider recently bought US$241k worth of stockOn the 8th of February, Philip Liang bought around 79k shares on-market at roughly US$3.05 per share. This transaction amounted to 4.9% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold US$670k more in shares than they bought in the last 12 months.Seeking Alpha • Feb 13Vicarious Surgical Non-GAAP EPS of -$0.16 beats by $0.02Vicarious Surgical press release (NYSE:RBOT): Q4 Non-GAAP EPS of -$0.16 beats by $0.02.Valuation Update With 7 Day Price Move • Feb 06Investor sentiment improves as stock rises 17%After last week's 17% share price gain to US$3.14, the stock trades at a trailing P/E ratio of 10.1x. Average forward P/E is 33x in the Medical Equipment industry in the US. Total loss to shareholders of 49% over the past year.お知らせ • Jan 31Vicarious Surgical Inc. to Report Q4, 2022 Results on Feb 13, 2023Vicarious Surgical Inc. announced that they will report Q4, 2022 results After-Market on Feb 13, 2023お知らせ • Jan 24Vicarious Surgical Inc. Announces Changes to Board of DirectorsVicarious Surgical Inc. announced the appointment of Victoria Carr-Brendel, Ph.D. to the Vicarious Surgical Board of Directors effective January 23, 2023. The Company also announced the resignation of technology-focused venture capitalist Phil Liang from the Vicarious Surgical Board of Directors effective as of today. Dr. Carr-Brendel possesses twenty-four years of medical device development experience leading R&D, new product development, divisional, and business development functions. She currently serves as the Group Vice President of Cochlear Implants at Sonova Group/President of Advanced Bionics, a Sonova company and a global leader in the treatment of severe-to-profound hearing loss. Prior to this, Dr. Carr-Brendel served as the Chief Executive Officer for JenaValve, a private company focused on developing transcatheter aortic valve repair systems to treat patients suffering from aortic valve disease. Between 2004 and 2015, she served in roles of increasing responsibility at Boston Scientific, eventually overseeing the acquisition of Bayer’s Interventional radiology division in 2014. Dr. Carr-Brendel received a Bachelor’s degree in Biology from Monmouth College, a Master of Science in Microbiology from Iowa State University, and a Ph.D. in Microbiology and Immunology from the University of Illinois at Chicago.Valuation Update With 7 Day Price Move • Jan 12Investor sentiment improved over the past weekAfter last week's 22% share price gain to US$2.33, the stock trades at a trailing P/E ratio of 7.5x. Average forward P/E is 32x in the Medical Equipment industry in the US. Total loss to shareholders of 70% over the past year.お知らせ • Dec 23Vicarious Surgical Completes Public Demonstration of Beta 2 Surgical Robotic SystemVicarious Surgical Inc. hosted the first public demonstration of its Beta 2 surgical robotic platform on December 6, 2022, highlighting the latest evolution of its differentiated technology and showcasing recent cadaveric testing. Supporting presentations by representatives from leading healthcare provider University Hospitals and renowned surgeon Dr. Igor Belyansky outlined the extensive opportunity for Vicarious to address current shortcomings in surgical robotics at the system and user level. As part of the Beta 2 Demonstration Day event, Dr. Belyansky reviewed intra-operative video of his recent cadaveric ventral hernia repair procedures in which he utilized the Vicarious Surgical Beta 2 system.Valuation Update With 7 Day Price Move • Dec 21Investor sentiment deteriorated over the past weekAfter last week's 25% share price decline to US$1.87, the stock trades at a trailing P/E ratio of 6x. Average forward P/E is 31x in the Medical Equipment industry in the US. Total loss to shareholders of 82% over the past year.Valuation Update With 7 Day Price Move • Dec 06Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to US$2.82, the stock trades at a trailing P/E ratio of 9.1x. Average forward P/E is 31x in the Medical Equipment industry in the US. Total loss to shareholders of 74% over the past year.Recent Insider Transactions • Nov 25Co-Founder recently sold US$74k worth of stockOn the 21st of November, Adam Sachs sold around 23k shares on-market at roughly US$3.25 per share. This transaction amounted to 17% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Adam has been a net seller over the last 12 months, reducing personal holdings by US$187k.Board Change • Nov 16High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. Independent Director Phil Liang is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Seeking Alpha • Nov 07Vicarious Surgical Non-GAAP EPS of -$0.18 misses by $0.03Vicarious Surgical (NYSE:RBOT): Q3 Non-GAAP EPS of -$0.18 misses by $0.03. Cash burn rate for the third quarter of 2022 was $14.5 million. The company had $126.8 million cash and equivalents as of September 30, 2022.Valuation Update With 7 Day Price Move • Oct 28Investor sentiment improved over the past weekAfter last week's 17% share price gain to US$3.73, the stock trades at a trailing P/E ratio of 25.7x. Average forward P/E is 28x in the Medical Equipment industry in the US. Total loss to shareholders of 71% over the past year.お知らせ • Oct 25Vicarious Surgical Inc. to Report Q3, 2022 Results on Nov 07, 2022Vicarious Surgical Inc. announced that they will report Q3, 2022 results After-Market on Nov 07, 2022Recent Insider Transactions Derivative • Oct 22CFO & Treasurer notifies of intention to sell stockWilliam Kelly intends to sell 15k shares in the next 90 days after lodging an Intent To Sell Form on the 18th of October. If the sale is conducted around the recent share price of US$3.65, it would amount to US$56k. Since December 2021, William's direct individual holding has increased from 2.07k shares to 15.52k. Company insiders have collectively sold US$1.3m more than they bought, via options and on-market transactions in the last 12 months.お知らせ • Oct 21Vicarious Surgical Inc. Announces Changes to Board of DirectorsVicarious Surgical Inc. announced the resignation of technology-focused venture capitalists Dror Berman and Samir Kaul from the Vicarious Surgical Board of Directors effective October 18, 2022. The Company also announced the appointment of Beverly Huss to the Vicarious Surgical Board of Directors, effective as of the same day. Ms. Huss will serve as a member of the Board’s Audit Committee. Ms. Huss co-founded and previously served as Chief Executive Officer of Pagonia Medical, a development stage company in the tissue preservation market, where she led the incorporation efforts and seed capital financing. Prior to this, Ms. Huss served over several years as Chief Executive Officer of Qool Therapeutics Inc., a therapeutic hypothermia and medical device company, and as Chief Executive Officer of Vibrynt Inc., a start-up medical device company dedicated to creating minimally invasive therapies for patients suffering from morbid obesity. From 1986 to 2005, Ms. Huss served in various general management roles of increasing responsibility within the research and development, regulatory affairs, marketing and sales departments of Guidant Corporation, a market leading medical device company focused on treatment of cardiac rhythm management, cardiovascular and peripheral vascular disease through minimally invasive therapies, until its acquisition by Boston Scientific Corporation. Ms. Huss is a veteran board member with nearly two decades of board experience and presently resides on the Boards of Accuray Incorporated, Ancora Heart Inc., Iridex Corporation and Madorra Inc. She received a Bachelor of Science in metallurgical engineering from the University of Illinois Urbana-Champaign and a Master’s degree in technology management from Pepperdine University.株主還元RBOTUS Medical EquipmentUS 市場7D-54.9%-1.0%1.4%1Y-97.1%-20.7%25.7%株主還元を見る業界別リターン: RBOT過去 1 年間で-20.7 % の収益を上げたUS Medical Equipment業界を下回りました。リターン対市場: RBOTは、過去 1 年間で25.7 % のリターンを上げたUS市場を下回りました。価格変動Is RBOT's price volatile compared to industry and market?RBOT volatilityRBOT Average Weekly Movement25.5%Medical Equipment Industry Average Movement8.8%Market Average Movement7.2%10% most volatile stocks in US Market16.8%10% least volatile stocks in US Market3.1%安定した株価: RBOTの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: RBOTの weekly volatility ( 26% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト201448Stephen Fromwww.vicarioussurgical.com米国でシングルポート手術ロボットを開発・販売。侵襲的な手術を行うために外科医を患者の体内に仮想的に運ぶシングルポート手術ロボット「Vicarious Surgical System」を提供している。同社は2014年に設立され、マサチューセッツ州ウォルサムに本社を置いている。もっと見るVicarious Surgical Inc. 基礎のまとめVicarious Surgical の収益と売上を時価総額と比較するとどうか。RBOT 基礎統計学時価総額US$1.64m収益（TTM）-US$42.12m売上高(TTM)n/a0.0xP/Sレシオ0.0xPER（株価収益率RBOT は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計RBOT 損益計算書（TTM）収益US$0売上原価US$0売上総利益US$0その他の費用US$42.12m収益-US$42.12m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-5.91グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率10.4%RBOT の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/21 14:47終値2026/06/18 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Vicarious Surgical Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Adam MaederPiper Sandler Companies
お知らせ • May 15Vicarious Surgical Inc Demonstrates Sustained System Performance And Complex Hernia Procedure Workflows In Pre-Clinical SettingVicarious Surgical Inc. announced the successful completion of a full-day synthetic abdominal model lab demonstrating sustained system performance and continued procedural workflow progression for the Vicarious Surgical System. During the lab, the Vicarious Surgical System operated fully draped for multiple hours while the CMO, an experienced abdominal surgeon, performed back-to-back IPOM+ and robotic transabdominal preperitoneal (rTAPP) ventral hernia repair workflows. The lab was conducted using the Company’s integrated instrument suite, including needle drivers, graspers, monopolar scissors and electrosurgical energy. The lab represents an important progression beyond the Company’s previously announced integrated benchtop testing milestone by extending validation of the Vicarious Surgical System into sustained procedural workflows under clinically relevant operating conditions. The testing demonstrated continued progress in runtime stability, visualization, instrument control and workflow execution as the Company advances toward design freeze and future cadaveric and in-vivo studies. The Company intends to continue expanding procedural workflow testing and system validation activities as it advances development of the Vicarious Surgical System for ventral hernia repair and other abdominal procedures.
お知らせ • Apr 01Vicarious Surgical Inc. Completes Integrated Benchtop Testing of Full Surgical Instrument Suite for Ventral Hernia RepairVicarious Surgical Inc. announced the successful completion of initial integrated benchtop testing for its full suite of surgical instruments, required for its anticipated first clinical indication of ventral hernia repair, marking an important step toward design validation, clinical readiness, and the Company’s targeted design freeze milestone. This milestone represents the first system-level performance evaluation of the Company's three core instruments: needle drivers, fenestrated graspers, and monopolar scissors, each of which is designed for use with the Vicarious Surgical System. The successful testing of all three instruments in a unified evaluation serves as a critical step in systematically de-risking the Company's path toward first-in-human use. Notably, the monopolar scissors, which previously demonstrated successful electrical performance in a December porcine lab study, exhibited strong motion and mechanical cutting capabilities following the Company's standard automated calibration and bring-up process. Importantly, instrument and camera sensors remained stable, with no degradation in video or motion quality in the presence of monopolar electrosurgical energy, confirming robust system performance under clinically relevant operating conditions. The successful completion of this benchtop testing positions the Company to advance to the next phase of preclinical validation, including planned cadaveric and porcine studies, as it continues to prepare for first clinical use of the Vicarious Surgical System and execute against a defined series of development milestones leading to design freeze.
お知らせ • Mar 07+ 9 more updatesVicarious Surgical Inc.(OTCPK:RBOT) dropped from Russell Microcap Value IndexVicarious Surgical Inc.(OTCPK:RBOT) dropped from Russell Microcap Value Index
新しいナラティブ • Mar 06Long-Term Robotic Surgery Adoption And Design Freeze Milestones Will Support A Bullish ThesisCatalysts About Vicarious Surgical Vicarious Surgical is developing a robotic surgical system designed for minimally invasive procedures. What are the underlying business or industry changes driving this perspective?
お知らせ • Mar 05Vicarious Surgical Inc. Receives Delisting Notice From NYSEOn March 3, 2026, the New York Stock Exchange (the NYSE) notified Vicarious Surgical Inc. (the Company) that the NYSE had determined to (A) immediately suspend trading in the Company's common stock, par value $0.0001 per share (the Common Stock), due to a determination that the Company had fallen below the NYSE's continued listing standard requiring listed companies to maintain an average global market capitalization over a consecutive 30 trading day period of at least $15,000,000 pursuant to Section 802.01B of the NYSE Listed Company Manual, and (B) commence proceedings to delist the Common Stock. The NYSE has stated that it will apply to the Securities and Exchange Commission to delist the Common Stock by filing a Form 25 upon completion of all applicable procedures, including any appeal by the Company of the NYSE's delisting determination, which appeal must be made within ten business days from receipt of the determination. The Company is currently evaluating whether to appeal the delisting determination. The Company has received approval of its application to have the Common Stock quoted on the OTCID market tier (OTCID) operated by the OTC Markets Group Inc. (OTC Markets). The Company expects that the Common Stock will commence quotation on the OTCID at the open of business on March 4, 2026 under the current trading symbol of RBOT. The OTCID is a significantly more limited market than the NYSE, and quotation on any OTC market will result in a less liquid market for existing and potential holders of the Common Stock to trade the Common Stock and could further depress the trading price of the Common Stock. The Company can provide no assurance that the Common Stock will continue to trade on this market, whether broker-dealers will provide and continue to provide public quotes of the Common Stock on this market, or whether the trading volume of the Common Stock will be sufficient to provide for an efficient trading market. The suspension and/or delisting of the Company's common stock from the NYSE could negatively impact the Company by (i) reducing the liquidity and market price of the Common Stock; (ii) reducing the number of investors willing to hold or acquire the Common Stock, which could negatively impact the Company's ability to raise equity financing; (iii) impacting the Company's ability to use a registration statement to offer and sell freely tradable securities, thereby preventing the Company from accessing the public capital markets; and (iv) impairing the Company's ability to provide equity incentives to its employees.
New Risk • Feb 21New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$51m net loss in 2 years). Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (US$13.1m market cap).
お知らせ • May 15Vicarious Surgical Inc Demonstrates Sustained System Performance And Complex Hernia Procedure Workflows In Pre-Clinical SettingVicarious Surgical Inc. announced the successful completion of a full-day synthetic abdominal model lab demonstrating sustained system performance and continued procedural workflow progression for the Vicarious Surgical System. During the lab, the Vicarious Surgical System operated fully draped for multiple hours while the CMO, an experienced abdominal surgeon, performed back-to-back IPOM+ and robotic transabdominal preperitoneal (rTAPP) ventral hernia repair workflows. The lab was conducted using the Company’s integrated instrument suite, including needle drivers, graspers, monopolar scissors and electrosurgical energy. The lab represents an important progression beyond the Company’s previously announced integrated benchtop testing milestone by extending validation of the Vicarious Surgical System into sustained procedural workflows under clinically relevant operating conditions. The testing demonstrated continued progress in runtime stability, visualization, instrument control and workflow execution as the Company advances toward design freeze and future cadaveric and in-vivo studies. The Company intends to continue expanding procedural workflow testing and system validation activities as it advances development of the Vicarious Surgical System for ventral hernia repair and other abdominal procedures.
お知らせ • Apr 01Vicarious Surgical Inc. Completes Integrated Benchtop Testing of Full Surgical Instrument Suite for Ventral Hernia RepairVicarious Surgical Inc. announced the successful completion of initial integrated benchtop testing for its full suite of surgical instruments, required for its anticipated first clinical indication of ventral hernia repair, marking an important step toward design validation, clinical readiness, and the Company’s targeted design freeze milestone. This milestone represents the first system-level performance evaluation of the Company's three core instruments: needle drivers, fenestrated graspers, and monopolar scissors, each of which is designed for use with the Vicarious Surgical System. The successful testing of all three instruments in a unified evaluation serves as a critical step in systematically de-risking the Company's path toward first-in-human use. Notably, the monopolar scissors, which previously demonstrated successful electrical performance in a December porcine lab study, exhibited strong motion and mechanical cutting capabilities following the Company's standard automated calibration and bring-up process. Importantly, instrument and camera sensors remained stable, with no degradation in video or motion quality in the presence of monopolar electrosurgical energy, confirming robust system performance under clinically relevant operating conditions. The successful completion of this benchtop testing positions the Company to advance to the next phase of preclinical validation, including planned cadaveric and porcine studies, as it continues to prepare for first clinical use of the Vicarious Surgical System and execute against a defined series of development milestones leading to design freeze.
お知らせ • Mar 07+ 9 more updatesVicarious Surgical Inc.(OTCPK:RBOT) dropped from Russell Microcap Value IndexVicarious Surgical Inc.(OTCPK:RBOT) dropped from Russell Microcap Value Index
新しいナラティブ • Mar 06Long-Term Robotic Surgery Adoption And Design Freeze Milestones Will Support A Bullish ThesisCatalysts About Vicarious Surgical Vicarious Surgical is developing a robotic surgical system designed for minimally invasive procedures. What are the underlying business or industry changes driving this perspective?
お知らせ • Mar 05Vicarious Surgical Inc. Receives Delisting Notice From NYSEOn March 3, 2026, the New York Stock Exchange (the NYSE) notified Vicarious Surgical Inc. (the Company) that the NYSE had determined to (A) immediately suspend trading in the Company's common stock, par value $0.0001 per share (the Common Stock), due to a determination that the Company had fallen below the NYSE's continued listing standard requiring listed companies to maintain an average global market capitalization over a consecutive 30 trading day period of at least $15,000,000 pursuant to Section 802.01B of the NYSE Listed Company Manual, and (B) commence proceedings to delist the Common Stock. The NYSE has stated that it will apply to the Securities and Exchange Commission to delist the Common Stock by filing a Form 25 upon completion of all applicable procedures, including any appeal by the Company of the NYSE's delisting determination, which appeal must be made within ten business days from receipt of the determination. The Company is currently evaluating whether to appeal the delisting determination. The Company has received approval of its application to have the Common Stock quoted on the OTCID market tier (OTCID) operated by the OTC Markets Group Inc. (OTC Markets). The Company expects that the Common Stock will commence quotation on the OTCID at the open of business on March 4, 2026 under the current trading symbol of RBOT. The OTCID is a significantly more limited market than the NYSE, and quotation on any OTC market will result in a less liquid market for existing and potential holders of the Common Stock to trade the Common Stock and could further depress the trading price of the Common Stock. The Company can provide no assurance that the Common Stock will continue to trade on this market, whether broker-dealers will provide and continue to provide public quotes of the Common Stock on this market, or whether the trading volume of the Common Stock will be sufficient to provide for an efficient trading market. The suspension and/or delisting of the Company's common stock from the NYSE could negatively impact the Company by (i) reducing the liquidity and market price of the Common Stock; (ii) reducing the number of investors willing to hold or acquire the Common Stock, which could negatively impact the Company's ability to raise equity financing; (iii) impacting the Company's ability to use a registration statement to offer and sell freely tradable securities, thereby preventing the Company from accessing the public capital markets; and (iv) impairing the Company's ability to provide equity incentives to its employees.
New Risk • Feb 21New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$51m net loss in 2 years). Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (US$13.1m market cap).
お知らせ • Jan 13Vicarious Surgical Advances Toward Design Freeze with Successful In-Vivo Porcine LabVicarious Surgical announced the successful completion of an in-vivo porcine lab conducted in December 2025, marking a meaningful step forward in the development of the company's robotic system and reinforcing progress toward system design freeze targeted for the end of 2026. During the lab, surgeons independently completed key elements of a ventral hernia repair using Vicarious Surgical's pre-DV system as part of a limited-scope feasibility assessment. In parallel, the company executed a series of targeted technical evaluations designed to assess system performance against key engineering and functional specifications. Data generated during the lab, along with structured surgeon feedback, are being incorporated into ongoing design refinement, verification planning, and system optimization efforts. The December in-vivo lab builds on Vicarious Surgical's disciplined, specification-driven development approach and reflects the company's focus on minimizing technical risk through iterative testing, surgeon engagement, and data-driven execution at this stage of system integration. This marks the Company's first in-vivo animal lab conducted in several years, and the first performed with an integrated system architecture rather than early-stage prototypes, providing critical insight into system behavior under realistic surgical conditions. The lab was conducted for research and development purposes only and was not designed to support regulatory submissions or clinical claims.
New Risk • Dec 26New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$51m net loss in 2 years). Market cap is less than US$100m (US$13.3m market cap).
お知らせ • Dec 13Vicarious Surgical Inc. has filed a Follow-on Equity Offering in the amount of $3 million.Vicarious Surgical Inc. has filed a Follow-on Equity Offering in the amount of $3 million. Security Name: Class A Common Stock Security Type: Common Stock Transaction Features: At the Market Offering
お知らせ • Dec 03Vicarious Surgical Inc. Announces Board and Committee ChangesOn December 1, 2025, Beverly Huss and Randy Clark each resigned as a member of the Board of Directors of Vicarious Surgical Inc., effective as of the Effective Date. Ms. Huss's and Mr. Clark's resignations were tendered in connection with a decision by the Board to reduce its size, and did not result from any disagreement regarding the Company's operations, policies or practices. In connection with Ms. Huss's and Mr. Clark's resignations, the Board reduced its size from nine members to seven as of the Effective Date. To address the resulting committee vacancies, Joseph Doherty was appointed as a member of the Audit Committee of the Board, Fuad Ahmad was appointed as a member of the Compensation Committee of the Board (the Compensation Committee"), and Victoria Carr-Brendel was appointed as Chair of the Compensation Committee, in each case effective as of the Effective Date.
New Risk • Nov 20New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 0.9% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 0.9% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$53m net loss in 2 years). Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (US$19.4m market cap).
Price Target Changed • Nov 13Price target decreased by 16% to US$9.00Down from US$10.75, the current price target is an average from 2 analysts. New target price is 159% above last closing price of US$3.48. Stock is down 67% over the past year. The company is forecast to post a net loss per share of US$7.99 next year compared to a net loss per share of US$10.74 last year.
お知らせ • Oct 31Vicarious Surgical Inc. to Report Q3, 2025 Results on Nov 13, 2025Vicarious Surgical Inc. announced that they will report Q3, 2025 results After-Market on Nov 13, 2025
New Risk • Oct 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings are forecast to decline by an average of 4.1% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$65m net loss in 2 years). Market cap is less than US$100m (US$39.2m market cap).
お知らせ • Oct 08Vicarious Surgical Inc. has filed a Follow-on Equity Offering in the amount of $5.864944 million.Vicarious Surgical Inc. has filed a Follow-on Equity Offering in the amount of $5.864944 million. Security Name: Class A Common stock Security Type: Common Stock Securities Offered: 588,300 Price\Range: $5.1 Discount Per Security: $0.306 Security Name: Pre-funded warrants Security Type: Equity Warrant Securities Offered: 561,700 Price\Range: $5.0999 Discount Per Security: $0.306 Transaction Features: Registered Direct Offering
お知らせ • Sep 26Vicarious Surgical Inc. Announces Appointment of Joseph Doherty as Chairman of the BoardVicarious Surgical Inc. announced the appointment of Joseph Doherty as Chairman of the Company’s Board of Directors . Mr. Doherty has served as a member of the Board since June 2025. Since January 2025, Mr. Doherty has served as CEO of the Worcester City Campus Corporation, a not-for-profit corporation whose base corporate purpose is to foster, promote and support the University of Massachusetts. Mr. Doherty has held a range of senior leadership positions across the healthcare and medical device industries. He served as President of Scapa Healthcare and sat on the Board of Directors of Scapa Group, a publicly traded company on the AIM Stock Exchange. He was also President of Olympus Surgical Technologies America, a subsidiary of Olympus Corporation of the Americas. Earlier in his career, he spent 24 years at Johnson & Johnson in roles of increasing responsibility, ultimately serving as Vice President of Integration and Transformation. In addition to his executive experience, Mr. Doherty has served on the boards of the Massachusetts Biomedical Initiative, Immertec, and ZATA Pharmaceuticals, and as an advisor to AccuTec and Boardwalk Robotics. He earned a Bachelor of Science in Engineering from the United States Military Academy at West Point and a Master of Business Administration from Nichols College.
お知らせ • Sep 17Vicarious Surgical Inc. Announces Board ChangesOn September 12, 2025, Donald Tang resigned as a member of the Board of Directors of Vicarious Surgical Inc. effective as of September 12, 2025. Mr. Tang’s resignation did not result from any disagreement regarding the Company’s operations, policies or practices. In connection with Mr. Tang’s resignation, the Board appointed Victoria Carr-Brendel as a member of the Audit Committee of the Board.
New Risk • Aug 28New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: US$49k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$50m free cash flow). Earnings are forecast to decline by an average of 4.1% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$65m net loss in 2 years). Share price has been volatile over the past 3 months (16% average weekly change). Significant insider selling over the past 3 months (US$49k sold). Market cap is less than US$100m (US$39.1m market cap).
New Risk • Aug 13New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 2.7% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$47m free cash flow). Earnings are forecast to decline by an average of 2.7% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$65m net loss in 2 years). Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (US$61.4m market cap).
お知らせ • Aug 01+ 1 more updateVicarious Surgical Inc. Announces Chief Executive Officer ChangesVicarious Surgical Inc. announced the appointment of Stephen From as Chief Executive Officer, effective August 7, 2025. Adam Sachs, current Chief Executive Officer, Co-Founder, and a member of the Board, will remain with the Company as President, Co-Founder, and a member of the Board in an operational capacity as a member of the Company’s leadership team. Mr. From brings over 20 years of leadership in the healthcare and financial industry. He most recently served as CEO of Aruna Bio, guiding the company’s strategic direction and clinical advancement of its proprietary neural exosome platform. From October 2005 through February 2021, Mr. From served as President and CEO, and from February 2021 through January 2022 served as Executive Chairman of Kiora Pharmaceuticals Inc., formerly known as EyeGate Pharmaceuticals Inc. Before EyeGate, Mr. From was CFO of Centelion SAS, then a biotech subsidiary of Sanofi-Aventis, and spent several years in investment banking, focusing on the life sciences sector at Bank of America Securities and Robertson Stephens. Mr. From holds a Bachelor of Science from the University of Western Ontario and earned his accounting designation from Wilfrid Laurier University.
お知らせ • Jul 30Vicarious Surgical Inc. to Report Q2, 2025 Results on Aug 12, 2025Vicarious Surgical Inc. announced that they will report Q2, 2025 results After-Market on Aug 12, 2025
分析記事 • Jul 15Here's Why We're A Bit Worried About Vicarious Surgical's (NYSE:RBOT) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
お知らせ • Jul 13The New York Stock Exchange Accepts Compliance Plan from Vicarious Surgical and to Quarterly Review to Confirm ComplianceAs previously reported, on April 10, 2025, Vicarious Surgical Inc. (the ‘Company’) received a written notice (the ‘Notice’) from the New York Stock Exchange (the ‘NYSE’) indicating the Company was no longer in compliance with the NYSE’s continued listing standards set forth in Section 802.01B of the NYSE’s Listed Company Manual (the ‘Minimum Market Capitalization Standard’) due to the fact that the Company’s average global market capitalization over a consecutive 30 trading-day period was less than $50 million and, at the same time, its stockholders’ equity was less than $50 million. In accordance with applicable NYSE procedures, the Company timely submitted a plan (the ‘Compliance Plan’) to the NYSE advising it of the definitive actions the Company has taken, is taking, and plans to take that would bring it into conformity with the Minimum Market Capitalization Standard within 18 months of receipt of the Notice (the ‘Cure Period’). On July 8, 2025, the NYSE notified the Company that it had accepted the Compliance Plan (the ‘Acceptance Letter’). The NYSE will review the Company on a quarterly basis to confirm compliance with the Compliance Plan. If the Company fails to comply with the Compliance Plan or does not meet the Minimum Market Capitalization Standard at the end of the Cure Period, it will be subject to NYSE’s prompt initiation of suspension and delisting procedures. The Acceptance Letter has no immediate impact on the listing of the Company’s Class A common stock, which will continue to be listed and traded on the NYSE during the Cure Period, subject to the Company’s continued compliance with the Compliance Plan and NYSE’s other continued listing standards. However, the Class A common stock trading symbol will have an added designation of ‘.BC’ to indicate that the status of the Class A common stock is below criteria with the NYSE continued listing standards. The ‘.BC’ indicator will be removed at such time as the Company regains compliance. The current noncompliance with the NYSE listing standards does not affect the Company’s ongoing business operations or its U.S. Securities and Exchange Commission (the ‘Commission’) reporting requirements. The Company is considering all available options to regain compliance with NYSE’s continued listing standards.
Board Change • Jul 02High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Fuad Ahmad was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Jun 30Vicarious Surgical Inc. Announces Changes to Its BoardVicarious Surgical Inc. announced the election of Fuad Ahmad and Joseph Doherty to the Board of Directors at the Company’s 2025 Annual Meeting of Stockholders held on June 27, 2025. The Company also announced the departure of Ric Fulop from the Board of Directors effective as of the Annual Meeting. Mr. Ahmad has been a partner at FLG Partners, a CEO and CFO consulting practice and board advisory services firm, since 2013. From November 2020 to March 2025, he served as CFO of Iridex Corporation, a medical device company. Prior to that, Mr. Ahmad served as CFO at each of Mitek Systems, Vaxart Inc., Cutera Inc., and Telenav Inc. Prior to joining FLG Partners, he served as CFO of Sezmi Corporation, a Morgenthaler Ventures-backed cloud-based software platform. Prior to his service with Sezmi Corporation, Mr. Ahmad served as Senior Vice President and CFO of Globalstar Inc., a public company that builds and operates low-earth orbit satellite-based digital telecommunications systems. Mr. Ahmad graduated from Brigham Young University with a Bachelor of Science in Finance. Mr. Doherty has served as CEO of the Worcester City Campus Corporation since January 2025. Since 2020, Mr. Doherty has served as a teacher at Saint John’s High School, and since March 2022, he has also served as a member of the board of directors of Immertec. From 2021 to 2025, he served as the Director for the BOLT initiative at the Massachusetts Biomedical Initiative. From January 2019 to August 2020, he served as the President of Scapa Healthcare, and from January 2019 to May 2020, he was a member of the board of directors of Scapa Group. From 2015 to 2019, Mr. Doherty served in roles of increasing responsibility, including as President of Olympus Surgical Technologies America. He also spent over 24 years with Johnson & Johnson and held various roles with increasing responsibilities, ultimately serving as the Vice President of Integration and Transformation. Mr. Doherty received a Bachelor of Science in Engineering from the United States Military Academy at West Point and a Master of Business Administration from Nichols College.
お知らせ • Apr 30Vicarious Surgical Inc., Annual General Meeting, Jun 27, 2025Vicarious Surgical Inc., Annual General Meeting, Jun 27, 2025.
New Risk • Apr 29New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 21% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$50m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$56m net loss in 3 years). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (US$50.2m market cap).
お知らせ • Apr 29Vicarious Surgical Inc. to Report Q1, 2025 Results on May 12, 2025Vicarious Surgical Inc. announced that they will report Q1, 2025 results After-Market on May 12, 2025
New Risk • Apr 26New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$50m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$56m net loss in 3 years). Market cap is less than US$100m (US$39.4m market cap).
お知らせ • Apr 12Vicarious Surgical Receives Continued Listing Standard Notice from the NYSEVicarious Surgical Inc. ("Vicarious Surgical" or the "Company") announced that on April 10, 2025, the Company received written notice (the "Notice") from the New York Stock Exchange (the "NYSE") indicating that the Company is no longer in compliance with the continued listing standards set under Section 802.01B of the NYSE's Listed Company Manual due to the fact that the Company's average market capitalization over a consecutive 30 trading-day period was less than $50 million and, at the same time, the Company's last reported stockholders' equity was less than $50 million. As set in the Notice, as of April 9, 2025, the 30 trading-day average market capitalization was approximately $47.4 million, and the Company's last reported stockholders' equity as of December 31, 2024 was less than $50 million. This notice does not impact the Company's business operations. In accordance with applicable NYSE procedures, the Company has 45 days from the date the Notice was received to submit a plan advising the NYSE of the definitive action(s) the Company has taken, is taking, or plans to take to bring it into compliance with Section 802.01B within 18 months of receipt of the Notice. If the Company's plan is not submitted on a timely basis or is not accepted, the NYSE will initiate delisting proceedings. Pending NYSE acceptance of the plan, the Company's Class A common stock will continue to be listed and traded on the NYSE during the 18-month cure period. Continued listing is also subject to the Company's compliance with other applicable NYSE requirements and to quarterly NYSE review of the Company's progress toward achieving compliance with the plan. In the interim, the Company's Class A common stock will continue to trade on the NYSE under the symbol "RBOT" with the designation of ".BC" to indicate the status of the shares as "below criteria," but is otherwise not immediately impacted by the Notice. The ".BC" indicator will be removed at such time as the Company regains compliance. The Notice also does not affect Securities and Exchange Commission reporting obligations by the Company. The Company is considering all available options to regain compliance with the NYSE's continued listing standards.
お知らせ • Mar 25Vicarious Surgical Inc. Announces Transition of Company President, Randy Clark to Board Member, Effective April 25, 2025Vicarious Surgical Inc. announced that Company President, Randy Clark, will transition to Board Member, effective April 25, 2025, pending customary conflict checks. As President, Mr. Clark directed critical business functions, including product development, operations, clinical regulatory, quality affairs, and human resources. He spearheaded the strategic development of Vicarious Surgical’s manufacturing capabilities, establishing key partnerships and strengthening the supply chain. Notably, he implemented key personnel realignment, streamlined business processes, and formalized workflows and standardized procedures in order to position the Company for its next phase of growth.
New Risk • Mar 18New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$51m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$51m free cash flow). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$56m net loss in 3 years). Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (US$56.9m market cap).
分析記事 • Mar 18Is Vicarious Surgical (NYSE:RBOT) In A Good Position To Deliver On Growth Plans?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
お知らせ • Mar 13Vicarious Surgical Appoints Sarah Romano as Chief Financial Officer, Effective from April 1, 2025Vicarious Surgical announced the appointment of Sarah Romano as Chief Financial Officer, Effective date is April 1, 2025. Ms. Romano will oversee Vicarious Surgical’s financial strategy, leveraging decades of financial leadership experience in capital markets. With exceptional strategic acumen, Ms. Romano has a proven record of driving growth and value creation in public companies, particularly in the healthcare sector, through successful fundraising and M&A initiatives. Most recently, Ms. Romano served as Chief Financial Officer of Entero Therapeutics, where she oversaw financial strategy, operations, and compliance, raising significant funding and successfully executing product in-licensing partnerships. Previously, as Chief Financial Officer of Kiora Pharmaceuticals, Ms. Romano secured over $50 million in funding and spearheaded M&A activities, overseeing due diligence and integration. Earlier in her career, Ms. Romano progressed through roles of increasing responsibility, including corporate controller, with responsibilities encompassing budget reviews, financial forecasting and analysis, internal controls oversight, and SEC reporting. Ms. Romano holds a Master of Accountancy from Boston College and a B.A. in Accounting from the College of the Holy Cross.
お知らせ • Mar 04Vicarious Surgical Inc. to Report Q4, 2024 Results on Mar 17, 2025Vicarious Surgical Inc. announced that they will report Q4, 2024 results at 4:00 PM, US Eastern Standard Time on Mar 17, 2025
お知らせ • Feb 19Vicarious Surgical Inc. Announces Chief Operating Officer Changes, Effective April 1, 2025Vicarious Surgical Inc. announced Chief Operating Officer (COO) John Mazzola will retire, effective April 1, 2025, after nearly 40 years in healthcare manufacturing, supply chain and quality control. Mr. Mazzola will continue to serve as COO until the effective date, at which time his responsibilities will transition to Randy Clark, Company President.
お知らせ • Dec 08Vicarious Surgical Inc. Announces Departure of William Kelly as Chief Financial Officer, Effective January 2, 2025Vicarious Surgical Inc. announced the pending departure of William Kelly, its Chief Financial Officer (CFO), to pursue other career opportunities, after nearly four years of dedicated service with the Company. Mr. Kelly has served as Vicarious Surgical’s CFO since January 2021. He will assist the Company to ensure minimal disruption and a successful transition of responsibilities prior to his departure, which is slated for January 2, 2025. The Company has initiated a CFO succession process and will provide updates as appropriate.
分析記事 • Nov 30We're Keeping An Eye On Vicarious Surgical's (NYSE:RBOT) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Price Target Changed • Nov 15Price target increased by 18% to US$11.17Up from US$9.50, the current price target is an average from 3 analysts. New target price is 19% above last closing price of US$9.36. Stock is up 0.6% over the past year. The company is forecast to post a net loss per share of US$11.04 next year compared to a net loss per share of US$14.60 last year.
New Risk • Nov 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings are forecast to decline by an average of 3.8% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$70m net loss in 3 years). Shareholders have been diluted in the past year (2.7% increase in shares outstanding). Market cap is less than US$100m (US$49.5m market cap).
お知らせ • Oct 29Vicarious Surgical Inc. to Report Q3, 2024 Results on Nov 12, 2024Vicarious Surgical Inc. announced that they will report Q3, 2024 results After-Market on Nov 12, 2024
分析記事 • Aug 16Here's Why Vicarious Surgical (NYSE:RBOT) Must Use Its Cash WiselyThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
お知らせ • Jul 30Vicarious Surgical Inc. to Report Q2, 2024 Results on Aug 12, 2024Vicarious Surgical Inc. announced that they will report Q2, 2024 results After-Market on Aug 12, 2024
Price Target Changed • Jul 16Price target increased by 21% to US$37.50Up from US$31.00, the current price target is an average from 2 analysts. New target price is 340% above last closing price of US$8.53. Stock is down 86% over the past year. The company is forecast to post a net loss per share of US$11.28 next year compared to a net loss per share of US$14.60 last year.
お知らせ • Apr 24Vicarious Surgical Inc., Annual General Meeting, Jun 10, 2024Vicarious Surgical Inc., Annual General Meeting, Jun 10, 2024, at 14:00 US Eastern Standard Time. Agenda: To elect seven directors to serve one-year terms expiring in 2025; to approve an amendment to the Vicarious Surgical Inc. 2021 Equity Incentive Plan (the Plan) to increase the number of shares of common stock authorized for issuance under the Plan by 5,000,000 shares; to approve an amendment to the Companys Certificate of Incorporation, as amended (the Certificate of Incorporation), to effect a reverse stock split.
お知らせ • Apr 09Vicarious Surgical Inc. to Report Q1, 2024 Results on Apr 29, 2024Vicarious Surgical Inc. announced that they will report Q1, 2024 results After-Market on Apr 29, 2024
New Risk • Mar 05New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 0.1% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (28% average weekly change). Earnings are forecast to decline by an average of 0.1% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$82m net loss in 3 years). Shareholders have been diluted in the past year (40% increase in shares outstanding). Market cap is less than US$100m (US$63.3m market cap).
分析記事 • Mar 05Is Vicarious Surgical (NYSE:RBOT) In A Good Position To Invest In Growth?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
お知らせ • Feb 13Vicarious Surgical Inc. to Report Q4, 2023 Results on Mar 04, 2024Vicarious Surgical Inc. announced that they will report Q4, 2023 results After-Market on Mar 04, 2024
お知らせ • Jan 30Vicarious Surgical Inc. Announces Management ChangesVicarious Surgical Inc. announced that Randy Clark has been appointed President effective, January 29, 2024. Reporting to Chief Executive Officer Adam Sachs, Mr. Clark will assume responsibility for the day-to-day oversight of many core business functions including product development, operations, commercial strategy, clinical, regulatory and quality affairs, and human resources. Mr. Clark joins as an accomplished leader with more than 20 years of medical device industry experience and has been instrumental in the development, manufacture, and commercialization of several innovative medical device solutions throughout his career. Most recently, Mr. Clark served as the Global President of the Health Solutions Business Unit at Flex Ltd., a prominent global supply chain, manufacturing, and design solutions provider. Prior to this, he spent 15 years at Olympus Corporation of the Americas, where he held various roles with increasing responsibilities, ultimately serving as President and a member of their board of directors, overseeing full P&L management for the Americas. Mr. Clark earned a Bachelor of Science in Business Administration from Drake University, a Master of Business Administration degree from Colorado State University, and completed the Advanced Management program at Harvard Business School. In connection with the appointment of Mr. Clark, Adam Sachs stepped down from his role as President. Mr. Sachs will continue to serve as the Chief Executive Officer of the Company.
分析記事 • Nov 24Is Vicarious Surgical (NYSE:RBOT) In A Good Position To Invest In Growth?We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Price Target Changed • Nov 17Price target decreased by 84% to US$1.13Down from US$7.00, the current price target is an average from 3 analysts. New target price is 319% above last closing price of US$0.27. Stock is down 92% over the past year. The company is forecast to post a net loss per share of US$0.56 compared to earnings per share of US$0.042 last year.
お知らせ • Oct 27Vicarious Surgical Inc. to Report Q3, 2023 Results on Nov 13, 2023Vicarious Surgical Inc. announced that they will report Q3, 2023 results After-Market on Nov 13, 2023
New Risk • Oct 03New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$89.6m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$50m net loss in 3 years). Shareholders have been diluted in the past year (41% increase in shares outstanding). Significant insider selling over the past 3 months (US$99k sold). Market cap is less than US$100m (US$89.6m market cap).
お知らせ • Sep 24Vicarious Surgical Receives Continued Listing Standard Notice From NYSEVicarious Surgical Inc. announced that on September 20, 2023, it received a notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that it is not in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company’s Class A common stock was less than $1.00 per share over a consecutive 30 trading-day period. The Notice does not result in the immediate delisting of the Company’s Class A common stock from the NYSE. The Company intends to respond to the NYSE within ten business days of receipt of the Notice affirming its intent to cure the stock price deficiency and to return to compliance with the NYSE continued listing standard. Pursuant to the NYSE’s rules, the Company has a six-month period following receipt of the Notice to regain compliance with the NYSE’s minimum share price requirement. The Company can regain compliance with the minimum share price requirement at any time during the cure period if, on the last trading day of any calendar month during the cure period, or on the last day of the cure period, the Company’s Class A common stock has (i) a closing share price of at least $1.00, and (ii) an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of that month or on the last day of the cure period, as applicable. The Company intends to consider available alternatives, including, but not limited to, a reverse stock split, subject to Board and stockholder approval at the Company’s next annual meeting, to regain compliance. The Company’s Class A common stock will continue to be listed and traded on the NYSE during this period, subject to its compliance with other NYSE continued listing standards. The receipt of the Notice does not affect the Company’s business, operations or reporting requirements with the Securities and Exchange Commission.
Seeking Alpha • Aug 24Vicarious Surgical: Huge Potential But Low Margin Of Safety To CommercializationSummary Vicarious Surgical is a surgical robotics company developing a next-generation surgical robot with human-like dexterity. The company has a large addressable market of over 45 million abdominal procedures worth $150 billion, but its survival is uncertain due to low cash reserves and high burn. I am personally staying on the sidelines as I believe the risk / reward is better if/when RBOT reaches commercialization with a superior product than currently awaiting regulatory approval. Read the full article on Seeking Alpha
New Risk • Aug 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$50m net loss in 3 years). Share price has been volatile over the past 3 months (15% average weekly change). Shareholders have been diluted in the past year (42% increase in shares outstanding). Significant insider selling over the past 3 months (US$147k sold).
分析記事 • Jul 18Here's Why We're Watching Vicarious Surgical's (NYSE:RBOT) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
お知らせ • Jul 14Vicarious Surgical Inc. to Report Q2, 2023 Results on Jul 27, 2023Vicarious Surgical Inc. announced that they will report Q2, 2023 results After-Market on Jul 27, 2023
New Risk • Jun 29New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: US$147k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$62m net loss in 3 years). Shareholders have been diluted in the past year (4.7% increase in shares outstanding). Significant insider selling over the past 3 months (US$147k sold).
Recent Insider Transactions • May 27Co-Founder recently sold US$54k worth of stockOn the 22nd of May, Adam Sachs sold around 24k shares on-market at roughly US$2.24 per share. This transaction amounted to 11% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Adam has been a net seller over the last 12 months, reducing personal holdings by US$325k.
Seeking Alpha • May 26Vicarious Surgical: Cash Burn Adds To Downside RiskSummary RBOT is attempting to commercialize a novel robotic surgery system with virtual reality capabilities. Commercialization is only expected in 2025 pending certifications and medical device approval. The company is bleeding cash and will likely require a major capital raise in the next year. Read the full article on Seeking Alpha
Recent Insider Transactions Derivative • May 26Co-Founder notifies of intention to sell stockAdam Sachs intends to sell 24k shares in the next 90 days after lodging an Intent To Sell Form on the 22nd of May. If the sale is conducted around the recent share price of US$2.07, it would amount to US$50k. For the year to December 2020, Adam's total compensation was 11% salary and 89% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since June 2022, Adam's direct individual holding has increased from 11.30m shares to 11.39m. Company insiders have collectively bought US$245k more than they sold, via options and on-market transactions, in the last 12 months.
お知らせ • May 19Vicarious Surgical Inc. Announces Promotion of John Mazzola to Chief Operating OfficerVicarious Surgical Inc. announced the promotion of John Mazzola to Chief Operating Officer. John joined Vicarious Surgical in March of 2022 as SVP of Operations and has over 35 years of medical device industry experience. He has been involved with over 25 medical device product launches encompassing both Class II and Class III devices. Prior to joining the Vicarious Surgical team, he spent 13 years in senior executive roles and product development leadership positions, including serving as VP of Operations at Becton Dickinson Surgery overseeing a network of 10 manufacturing sites, a business planning and procurement organization, an advanced manufacturing engineering team, and the business’ environmental health and safety responsibilities. In the past year, John has led strategic manufacturing plans for the Vicarious Surgical robotic system, overseeing operations and quality organizations. In the newly created Chief Operating Officer role, John’s oversight expands to include the Product Development, Clinical & Regulatory Affairs, IT and People & Culture functions of the business for enhanced workflow efficiency and a continued focus on manufacturing and procurement optimization.
Recent Insider Transactions • Mar 31Insider recently bought US$153k worth of stockOn the 27th of March, Philip Liang bought around 74k shares on-market at roughly US$2.07 per share. This transaction amounted to 3.6% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth US$241k. Insiders have collectively bought US$220k more in shares than they have sold in the last 12 months.
Valuation Update With 7 Day Price Move • Mar 25Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to US$1.90, the stock trades at a trailing P/E ratio of 46.4x. Average forward P/E is 31x in the Medical Equipment industry in the US. Total loss to shareholders of 57% over the past year.
Recent Insider Transactions • Mar 17Insider recently bought US$139k worth of stockOn the 13th of March, Philip Liang bought around 59k shares on-market at roughly US$2.36 per share. This transaction amounted to 3.1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth US$241k. Despite this recent purchase, insiders have collectively sold US$134k more in shares than they bought in the last 12 months.
Recent Insider Transactions • Mar 10Insider recently bought US$78k worth of stockOn the 2nd of March, Philip Liang bought around 30k shares on-market at roughly US$2.60 per share. This transaction amounted to 1.7% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth US$241k. Despite this recent purchase, insiders have collectively sold US$366k more in shares than they bought in the last 12 months.
Recent Insider Transactions • Feb 27Co-Founder recently sold US$65k worth of stockOn the 21st of February, Adam Sachs sold around 24k shares on-market at roughly US$2.78 per share. This transaction amounted to 14% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Adam has been a net seller over the last 12 months, reducing personal holdings by US$260k.
Recent Insider Transactions Derivative • Feb 26Co-Founder notifies of intention to sell stockAdam Sachs intends to sell 24k shares in the next 90 days after lodging an Intent To Sell Form on the 21st of February. If the sale is conducted around the recent share price of US$3.06, it would amount to US$72k. For the year to December 2020, Adam's total compensation was 5% salary and 95% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2022, Adam's direct individual holding has increased from 11.33m shares to 11.34m. Company insiders have collectively sold US$906k more than they bought, via options and on-market transactions in the last 12 months.
Valuation Update With 7 Day Price Move • Feb 22Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to US$2.75, the stock trades at a trailing P/E ratio of 67.2x. Average forward P/E is 32x in the Medical Equipment industry in the US. Total loss to shareholders of 51% over the past year.
Price Target Changed • Feb 16Price target decreased by 21% to US$7.75Down from US$9.75, the current price target is an average from 4 analysts. New target price is 139% above last closing price of US$3.24. Stock is down 47% over the past year. The company is forecast to post a net loss per share of US$0.59 compared to earnings per share of US$0.042 last year.
Recent Insider Transactions • Feb 14Insider recently bought US$241k worth of stockOn the 8th of February, Philip Liang bought around 79k shares on-market at roughly US$3.05 per share. This transaction amounted to 4.9% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold US$670k more in shares than they bought in the last 12 months.
Seeking Alpha • Feb 13Vicarious Surgical Non-GAAP EPS of -$0.16 beats by $0.02Vicarious Surgical press release (NYSE:RBOT): Q4 Non-GAAP EPS of -$0.16 beats by $0.02.
Valuation Update With 7 Day Price Move • Feb 06Investor sentiment improves as stock rises 17%After last week's 17% share price gain to US$3.14, the stock trades at a trailing P/E ratio of 10.1x. Average forward P/E is 33x in the Medical Equipment industry in the US. Total loss to shareholders of 49% over the past year.
お知らせ • Jan 31Vicarious Surgical Inc. to Report Q4, 2022 Results on Feb 13, 2023Vicarious Surgical Inc. announced that they will report Q4, 2022 results After-Market on Feb 13, 2023
お知らせ • Jan 24Vicarious Surgical Inc. Announces Changes to Board of DirectorsVicarious Surgical Inc. announced the appointment of Victoria Carr-Brendel, Ph.D. to the Vicarious Surgical Board of Directors effective January 23, 2023. The Company also announced the resignation of technology-focused venture capitalist Phil Liang from the Vicarious Surgical Board of Directors effective as of today. Dr. Carr-Brendel possesses twenty-four years of medical device development experience leading R&D, new product development, divisional, and business development functions. She currently serves as the Group Vice President of Cochlear Implants at Sonova Group/President of Advanced Bionics, a Sonova company and a global leader in the treatment of severe-to-profound hearing loss. Prior to this, Dr. Carr-Brendel served as the Chief Executive Officer for JenaValve, a private company focused on developing transcatheter aortic valve repair systems to treat patients suffering from aortic valve disease. Between 2004 and 2015, she served in roles of increasing responsibility at Boston Scientific, eventually overseeing the acquisition of Bayer’s Interventional radiology division in 2014. Dr. Carr-Brendel received a Bachelor’s degree in Biology from Monmouth College, a Master of Science in Microbiology from Iowa State University, and a Ph.D. in Microbiology and Immunology from the University of Illinois at Chicago.
Valuation Update With 7 Day Price Move • Jan 12Investor sentiment improved over the past weekAfter last week's 22% share price gain to US$2.33, the stock trades at a trailing P/E ratio of 7.5x. Average forward P/E is 32x in the Medical Equipment industry in the US. Total loss to shareholders of 70% over the past year.
お知らせ • Dec 23Vicarious Surgical Completes Public Demonstration of Beta 2 Surgical Robotic SystemVicarious Surgical Inc. hosted the first public demonstration of its Beta 2 surgical robotic platform on December 6, 2022, highlighting the latest evolution of its differentiated technology and showcasing recent cadaveric testing. Supporting presentations by representatives from leading healthcare provider University Hospitals and renowned surgeon Dr. Igor Belyansky outlined the extensive opportunity for Vicarious to address current shortcomings in surgical robotics at the system and user level. As part of the Beta 2 Demonstration Day event, Dr. Belyansky reviewed intra-operative video of his recent cadaveric ventral hernia repair procedures in which he utilized the Vicarious Surgical Beta 2 system.
Valuation Update With 7 Day Price Move • Dec 21Investor sentiment deteriorated over the past weekAfter last week's 25% share price decline to US$1.87, the stock trades at a trailing P/E ratio of 6x. Average forward P/E is 31x in the Medical Equipment industry in the US. Total loss to shareholders of 82% over the past year.
Valuation Update With 7 Day Price Move • Dec 06Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to US$2.82, the stock trades at a trailing P/E ratio of 9.1x. Average forward P/E is 31x in the Medical Equipment industry in the US. Total loss to shareholders of 74% over the past year.
Recent Insider Transactions • Nov 25Co-Founder recently sold US$74k worth of stockOn the 21st of November, Adam Sachs sold around 23k shares on-market at roughly US$3.25 per share. This transaction amounted to 17% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Adam has been a net seller over the last 12 months, reducing personal holdings by US$187k.
Board Change • Nov 16High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. Independent Director Phil Liang is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Seeking Alpha • Nov 07Vicarious Surgical Non-GAAP EPS of -$0.18 misses by $0.03Vicarious Surgical (NYSE:RBOT): Q3 Non-GAAP EPS of -$0.18 misses by $0.03. Cash burn rate for the third quarter of 2022 was $14.5 million. The company had $126.8 million cash and equivalents as of September 30, 2022.
Valuation Update With 7 Day Price Move • Oct 28Investor sentiment improved over the past weekAfter last week's 17% share price gain to US$3.73, the stock trades at a trailing P/E ratio of 25.7x. Average forward P/E is 28x in the Medical Equipment industry in the US. Total loss to shareholders of 71% over the past year.
お知らせ • Oct 25Vicarious Surgical Inc. to Report Q3, 2022 Results on Nov 07, 2022Vicarious Surgical Inc. announced that they will report Q3, 2022 results After-Market on Nov 07, 2022
Recent Insider Transactions Derivative • Oct 22CFO & Treasurer notifies of intention to sell stockWilliam Kelly intends to sell 15k shares in the next 90 days after lodging an Intent To Sell Form on the 18th of October. If the sale is conducted around the recent share price of US$3.65, it would amount to US$56k. Since December 2021, William's direct individual holding has increased from 2.07k shares to 15.52k. Company insiders have collectively sold US$1.3m more than they bought, via options and on-market transactions in the last 12 months.
お知らせ • Oct 21Vicarious Surgical Inc. Announces Changes to Board of DirectorsVicarious Surgical Inc. announced the resignation of technology-focused venture capitalists Dror Berman and Samir Kaul from the Vicarious Surgical Board of Directors effective October 18, 2022. The Company also announced the appointment of Beverly Huss to the Vicarious Surgical Board of Directors, effective as of the same day. Ms. Huss will serve as a member of the Board’s Audit Committee. Ms. Huss co-founded and previously served as Chief Executive Officer of Pagonia Medical, a development stage company in the tissue preservation market, where she led the incorporation efforts and seed capital financing. Prior to this, Ms. Huss served over several years as Chief Executive Officer of Qool Therapeutics Inc., a therapeutic hypothermia and medical device company, and as Chief Executive Officer of Vibrynt Inc., a start-up medical device company dedicated to creating minimally invasive therapies for patients suffering from morbid obesity. From 1986 to 2005, Ms. Huss served in various general management roles of increasing responsibility within the research and development, regulatory affairs, marketing and sales departments of Guidant Corporation, a market leading medical device company focused on treatment of cardiac rhythm management, cardiovascular and peripheral vascular disease through minimally invasive therapies, until its acquisition by Boston Scientific Corporation. Ms. Huss is a veteran board member with nearly two decades of board experience and presently resides on the Boards of Accuray Incorporated, Ancora Heart Inc., Iridex Corporation and Madorra Inc. She received a Bachelor of Science in metallurgical engineering from the University of Illinois Urbana-Champaign and a Master’s degree in technology management from Pepperdine University.
